Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables - Net (2019 - 2021)

Historic Receivables - Net for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Q4 2021 value amounting to $47000.0.

  • 4D Molecular Therapeutics' Receivables - Net fell 9683.71% to $47000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $47000.0, marking a year-over-year decrease of 9683.71%. This contributed to the annual value of $47000.0 for FY2021, which is 9683.71% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Receivables - Net stood at $47000.0 for Q4 2021, which was down 9683.71% from $791000.0 recorded in Q3 2021.
  • 4D Molecular Therapeutics' Receivables - Net's 5-year high stood at $1.5 million during Q4 2020, with a 5-year trough of $47000.0 in Q4 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Receivables - Net value was $884500.0 (recorded in 2019), while the average stood at $825500.0.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Receivables - Net soared by 5194.27% in 2020 and then tumbled by 9683.71% in 2021.
  • 4D Molecular Therapeutics' Receivables - Net (Quarter) stood at $978000.0 in 2019, then skyrocketed by 51.94% to $1.5 million in 2020, then plummeted by 96.84% to $47000.0 in 2021.
  • Its last three reported values are $47000.0 in Q4 2021, $791000.0 for Q3 2021, and $1.5 million during Q4 2020.